Apaziquone

Overview of the drug Apaziquone

Apaziquone
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Apaziquone is a bioreductive prodrug that is being investigated for its potential use in the treatment of bladder cancer. It is a derivative of the quinone family and is designed to be activated in the hypoxic environment of tumors.

Mechanism of Action

Apaziquone is activated by reductive enzymes in the low-oxygen environment of cancer cells. Once activated, it forms cytotoxic species that can induce DNA damage and lead to cell death. This selective activation is intended to minimize damage to healthy, oxygenated tissues.

Clinical Applications

Apaziquone is primarily being studied for its use in non-muscle invasive bladder cancer (NMIBC). It is administered intravesically, meaning it is directly instilled into the bladder, allowing for high local concentrations of the drug with reduced systemic exposure.

Development and Trials

Clinical trials have been conducted to evaluate the efficacy and safety of Apaziquone in patients with NMIBC. These trials aim to determine the optimal dosing regimen and to assess the potential benefits of Apaziquone in reducing tumor recurrence.

Chemical Properties

Chemical structure of Apaziquone

Apaziquone is a synthetic analog of the naturally occurring compound mitomycin C. Its chemical structure allows it to undergo bioreductive activation, a key feature in its mechanism of action.

Side Effects

The side effects of Apaziquone are generally related to its local administration and include bladder irritation, hematuria, and dysuria. Systemic side effects are rare due to the localized nature of the treatment.

Related pages

• Bladder cancer
• Mitomycin C
• Prodrug
• Chemotherapy